In the I-SPY 2 TRIAL, the MK2206 experimental arm was opento all HR/HER2 tumor subtypes, and gene expression arrays and a panel ofproteomic/phospho-proteomic biomarkers were assayed in all pretreatment biopsysamples. This evidence concerns the gene ERBB2 and neoplasm.